ITCI - Intra-Cellular Therapies, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
New York,
United States
Type: Equity
ITCI price evolution
ITCI
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $695.06 | $141.57 | $149.52 | |
| Short term investments | $329.6 | $335.8 | $350.17 | |
| Net receivables | $145.61 | $145.71 | $131.16 | $114.02 |
| Inventory | $23.54 | $52.64 | $50.77 | $50.27 |
| Total current assets | $1271.73 | $1264.25 | $690.53 | $667.8 |
| Long term investments | ||||
| Property, plant & equipment | $16.02 | $15.95 | $14 | $14.58 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $56.25 | $56.51 | $60.5 | |
| Total investments | $329.6 | $335.8 | $350.17 | |
| Total assets | $1324.44 | $1320.5 | $747.04 | $728.29 |
| Current liabilities | ||||
| Accounts payable | $10.34 | $17.55 | $11.53 | $11.45 |
| Deferred revenue | ||||
| Short long term debt | $4.17 | $3.64 | $3.61 | |
| Total current liabilities | $166.11 | $161.78 | $134.8 | $123.55 |
| Long term debt | $14.12 | $12.74 | $13.33 | |
| Total noncurrent liabilities | $14.12 | $12.74 | $13.33 | |
| Total debt | $18.29 | $16.38 | $16.94 | |
| Total liabilities | $179.62 | $175.89 | $147.54 | $136.87 |
| Shareholders' equity | ||||
| Retained earnings | -$1674.95 | -$1648.63 | -$1632.41 | -$1617.16 |
| Other shareholder equity | $1.63 | -$0.67 | -$0.43 | $0.1 |
| Total shareholder equity | $1144.61 | $599.5 | $591.42 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $149.52 | $150.37 | $93.76 | $61.45 |
| Short term investments | $350.17 | $443.29 | $319.97 | $597.4 |
| Net receivables | $114.02 | $75.19 | $20.16 | $10.76 |
| Inventory | $50.27 | $23.92 | $7.95 | $7.06 |
| Total current assets | $667.8 | $737.96 | $467.28 | $690.9 |
| Long term investments | ||||
| Property, plant & equipment | $14.58 | $16.74 | $22.56 | $26.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $60.5 | $16.82 | $22.64 | $26.41 |
| Total investments | $350.17 | $443.29 | $319.97 | $597.4 |
| Total assets | $728.29 | $754.78 | $489.92 | $717.31 |
| Current liabilities | ||||
| Accounts payable | $11.45 | $10.39 | $8.69 | $5.5 |
| Deferred revenue | ||||
| Short long term debt | $3.61 | $4.57 | $6.73 | $5.54 |
| Total current liabilities | $123.55 | $83.24 | $53.36 | $36.85 |
| Long term debt | $13.33 | $15.47 | $18.67 | $23.6 |
| Total noncurrent liabilities | $13.33 | $15.47 | $18.67 | $23.6 |
| Total debt | $16.94 | $20.04 | $25.41 | $29.14 |
| Total liabilities | $136.87 | $98.71 | $72.03 | $60.45 |
| Shareholders' equity | ||||
| Retained earnings | -$1617.16 | -$1477.49 | -$1221.23 | -$937.1 |
| Other shareholder equity | $0.1 | -$4.19 | -$0.36 | $0.48 |
| Total shareholder equity | $591.42 | $656.07 | $417.89 | $656.86 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $161.39 | $144.87 | $132.1 | |
| Cost of revenue | $11.35 | $9.9 | $10.7 | |
| Gross Profit | $150.03 | $134.97 | $121.4 | |
| Operating activities | ||||
| Research & development | $56.18 | $42.83 | $50.77 | |
| Selling, general & administrative | $121.57 | $113.08 | $104.72 | |
| Total operating expenses | $177.76 | $155.92 | $155.49 | |
| Operating income | -$27.72 | -$20.95 | -$34.1 | |
| Income from continuing operations | ||||
| EBIT | -$16.16 | -$14.89 | -$28.13 | |
| Income tax expense | $0.06 | $0.36 | $0.45 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$16.22 | -$15.25 | -$28.58 | |
| Income (for common shares) | -$16.22 | -$15.25 | -$28.58 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $464.37 | $250.31 | $83.8 | $22.81 |
| Cost of revenue | $33.74 | $20.44 | $8.03 | $1.9 |
| Gross Profit | $430.63 | $229.87 | $75.77 | $20.92 |
| Operating activities | ||||
| Research & development | $180.14 | $134.72 | $88.85 | $65.78 |
| Selling, general & administrative | $409.86 | $358.78 | $272.61 | $186.36 |
| Total operating expenses | $590.01 | $493.5 | $361.46 | $252.15 |
| Operating income | -$159.38 | -$263.63 | -$285.69 | -$231.23 |
| Income from continuing operations | ||||
| EBIT | -$139.04 | -$256.25 | -$284.12 | -$226.99 |
| Income tax expense | $0.64 | $0.01 | $0.01 | $0.01 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$139.67 | -$256.26 | -$284.13 | -$227.01 |
| Income (for common shares) | -$139.67 | -$256.26 | -$284.13 | -$227.01 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$16.22 | -$15.25 | -$28.58 | |
| Operating activities | ||||
| Depreciation | $0.13 | $0.13 | $0.14 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $16.39 | $13.87 | $14.88 | |
| Total cash flows from operations | $0.54 | -$34.12 | -$2.06 | |
| Investing activities | ||||
| Capital expenditures | -$0.05 | -$0 | ||
| Investments | $7.82 | $16.18 | $47.42 | |
| Total cash flows from investing | -$185.26 | $7.77 | $16.18 | $47.42 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $545.18 | $9.99 | $3 | |
| Net borrowings | ||||
| Total cash flows from financing | $561.9 | $545.18 | $9.99 | $3 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $316.55 | $553.49 | -$7.95 | $48.37 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$139.67 | -$256.26 | -$284.13 | -$227.01 |
| Operating activities | ||||
| Depreciation | $0.53 | $0.66 | $0.53 | $0.53 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $52.92 | $43.1 | $34.48 | $24.33 |
| Total cash flows from operations | -$124.2 | -$270.19 | -$259.54 | -$230.07 |
| Investing activities | ||||
| Capital expenditures | -$0.27 | -$0.78 | -$0.33 | -$0.27 |
| Investments | $105.81 | -$127.59 | $280.67 | -$480.03 |
| Total cash flows from investing | $105.54 | -$128.37 | $280.34 | -$480.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.81 | $455.16 | $11.52 | $664.18 |
| Net borrowings | ||||
| Total cash flows from financing | $17.81 | $455.16 | $11.52 | $664.18 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.85 | $56.6 | $32.32 | -$46.19 |
News
Fundamentals
| Market cap | $9.06B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 106.00M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.23 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.66 |
| Quick ratio | 7.51 |